newsfilter
← Latest News
PR Newswire·

Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint

- Lonafarnib/ritonavir response rate of 10.1% (p=0.0044)- Lonafarnib/ritonavir in combination with peginterferon alfa response rate of 19.2% (p<0.0001)- Peginterferon alfa comparator arm, included for contribution